Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Terminated 1

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Neoplasms 9Carcinoma, Non-Small-Cell Lung 7Colorectal Neoplasms 6Breast Neoplasms 6Prostatic Neoplasms 5Papillomavirus Infections 5Ovarian Neoplasms 4Neoplastic Cells, Circulating 4Uterine Cervical Neoplasms 3Uterine Cervical Dysplasia 3Lung Neoplasms 3Melanoma 2Lymphoma, Follicular 2Leukemia, Myeloid, Acute 2Hematologic Neoplasms 2Carcinoma, Hepatocellular 2Thymic aplasia 1Stomach Neoplasms 1Solid Tumor, Adult 1Small Cell Lung Carcinoma 1Respiratory Distress Syndrome 1Recurrence 1Rectal Neoplasms 1Radiation Injuries 1Pulmonary Disease, Chronic Obstructive 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Precancerous Conditions 1Pancreatic Neoplasms 1Osteosarcoma 1Opioid-Related Disorders 1

Interventions

Temozolomide 6Granulocyte-Macrophage Colony-Stimulating Factor 6Cyclophosphamide 6Topotecan 5Isotretinoin 5Irinotecan 53-Iodobenzylguanidine 4naxitamab 3dinutuximab 3Vincristine 3venetoclax 2trametinib 2ribociclib 2racotumomab 2omburtamab I-131 2fludarabine 2dabrafenib 23-fluorobenzylguanidine 2sonidegib 1robatumumab 1regorafenib 1plerixafor 1palbociclib 1niraparib 1molibresib 1lorlatinib 1entrectinib 1dostarlimab 1copanlisib 1ceritinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Neuroblastoma × Blood Specimen Collection × Clear all
NCT03860207 2023-09-13

Study of the Safety and Efficacy of Humanized 3F8 Bispecific Antibody (Hu3F8-BsAb) in Patients With Relapsed/Refractory Neuroblastoma, Osteosarcoma and Other Solid Tumor Cancers

Y-mAbs Therapeutics

Phase 1/2 Terminated
12 enrolled 15 charts
CNSSarcoma

Neuroblastoma, Osteosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡